20/20 Biolabs Inc (NASDAQ:AIDX) Shares Shorted: Short Interest Up 405.8% in October

20/20 Biolabs Inc (NASDAQ:AIDX) saw a large increase in short interest in October. As of October 30th, there was short interest totaling 57,001 shares, an increase of 405.8% from the October 15th total of 11,270 shares. Based on an average trading volume of 160,271 shares, the short-interest ratio is presently 0.4 days. Approximately 0.6% of the shares of the stock are short sold.

20/20 Biolabs Stock Performance

Shares of AIDX stock opened at $0.20 on Wednesday. 20/20 Biolabs has a fifty-two week low of $0.18 and a fifty-two week high of $50.00. The company has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.96. The stock has a market capitalization of $2.61 million and a P/E ratio of -0.36.

20/20 Biolabs (NASDAQ:AIDX) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $0.73 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of 20/20 Biolabs in a report on Friday, October 30th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.